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There have been many calls for more information about the natural resistome and
these have also highlighted the importance of understanding the soil resistome in the
preservation of antibiotics for the treatment of infections. However, to date there have
been fewstudieswhich have investigated the culturable soil resistome, which highlights the
difficulties faced by microbiologists in designing these experiments to produce meaningful
data.TheWorld Health Organization definition of resistance is themost fitting to non-clinical
environmental studies: antimicrobial resistance is resistance of a microorganism to an
antimicrobial medicine to which it was previously sensitive. The ideal investigation of
non-clinical environments for antibiotic resistance of clinical relevance would be using
standardized guidelines and breakpoints. This review outlines different definitions and
methodologies used to understand antibiotic resistance and suggests how this can be
performed outside of the clinical environment.
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The World Health Organization World Health Day 2011 high-
lighted the problems of antibiotic resistance under the title
“Antibiotic resistance: no action today, no cure tomorrow”. Every
year 25,000 people in the European Union die because of a seri-
ous resistant bacterial infection, mostly acquired in health care
settings1. The search for antibiotics, understanding their mech-
anisms of action and the development and spread of antibiotic
resistance has resulted in the development of many industries
and novel research areas for over 100 years. However, the num-
ber of antibiotics coming to the market over the past 30 years
has dramatically declined as many pharmaceutical companies and
biotech firms abandoned the search for antibiotics in favor of other
pharmaceuticals (Spellberg et al., 2004). Antibiotic resistance has
developed over time from resistance to single classes of antibi-
otics to multi-drug resistance and extreme drug resistance. Until
recently, antibiotics and antibiotic resistance were thought of in
terms of treatments of infections and the prevention of successful
treatment, respectively. The mechanisms of action and resistance
have been studied almost exclusively in pathogenic bacteria. It
is only in recent years that research in antibiotic resistance has
focused on the environment from which the antibiotics were ini-
tially extracted: soil microorganisms and the soil ecosystem. With
an every decreasing supply of novel antibiotics and increasing
resistance the emphasis has turned to defining the natural antibi-
otic resistome and understanding the ecology and evolution of
antibiotic resistance in the non-clinical environment. These recent
research focuses are thought to bring answers to help prevent a
return to the pre-antibiotic era.
There have beenmany calls formore information about thenat-
ural resistome and these have also highlighted the importance of
understanding the soil resistome in the preservation of antibiotics
1http://www.who.int/world-health-day/2011/en/
for the treatment of infections (Pruden et al., 2006; American
Academy of Microbiology, 2009; Aminov, 2009; Rosenblatt-
Farrell, 2009). However, to date there have been few studies which
have investigated the culturable soil resistome, in antibiotic pro-
ducing bacteria Streptomyces, and an isolated cave microbiome
(D’Costa et al., 2006; Bhullar et al., 2012). Numerous studies have
been performedusing polymerase chain reaction (PCR) or quanti-
tative PCR (qPCR) to screen the environment for known resistance
genes or more recently metagenomics (Volkmann et al., 2004;
Chen et al., 2007; Knapp et al., 2008; Lata et al., 2009; Zhang et al.,
2011; McGarvey et al., 2012; Popowska et al., 2012). Functional
metagenomics have also been used to identify novel resistance
mechanisms in soil (Allen et al., 2009; Donato et al., 2010; Torres-
Cortés et al., 2011). The identification of antibiotic resistance
hotspots and the understanding of the evolution and ecology of
antibiotic resistance in the environment are novel areas of research.
There have been more reviews written on this topic that research
papers to date, which highlights the difficulties faced by micro-
biologists in designing these experiments to produce meaningful
data. We are faced with some fundamental difficulties in assessing
and analyzing the environmental antibiotic resistome.
Antibiotic resistance and antibiotic breakpoints have been
defined within the context of their medical functions. Clini-
cal breakpoints define bacteria as susceptible, intermediate, or
resistant to an antibiotic and are calculated using several fac-
tors, including clinical results from studies, wild type minimum
inhibitory concentration (MIC) distributions for the relevant bac-
terial species, antibiotic dosing and pharmacokinetic (PK) and
pharmacodynamics (PD) measurements (Clinical and Labora-
tory Standards Institute [CLSI], 2006; European Committee on
Antimicrobial Susceptibility Testing [EUCAST], 2011). This is
used as a guide for the clinician to decide how to treat the patient,
with antibiotic resistance meaning treatment failure. But what
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does antibiotic resistance mean out-with the human health or
infection treatment context?Weneed to also definewhat an antibi-
otic is in the natural environment, as this too is a term adapted for
use in terms of treating bacterial infections.
The soilmay be a reservoir of resistance genes,which are already
present in human pathogens or which may emerge to increase the
current arsenal of antibiotic resistance mechanisms in pathogens.
Most antibiotics used in human medicine have been isolated from
soil microorganisms. Therefore, soil is thought of as a potential
reservoir of antibiotic resistance genes. The presence of antibiotics
in soil is believed to have promoted the development of highly
specific antibiotic resistance mechanisms in antibiotic producing
and non-producing bacteria (D’Costa et al., 2006). This belief is
based on studies, which have identified resistance genes such as
blaCTX-M, qnrA, and blaNDM as originating in the environmen-
tal bacteria Kluyvera spp., Shewanella algae, and Erythrobacter
litoralis, respectively (Oliver et al., 2001; Nordmann and Poirel,
2005; Zheng et al., 2011). These genes are clinically relevant resis-
tance genes and are currently causing difficulties in the treatment
of bacterial infections. The origins of other plasmid mediated
resistance genes are still unknown. Anthropocentrism has led to
the view that genes such as blaCTX−M, qnrA, and blaNDM have
evolved in nature as antibiotic resistance genes. However, the true
functions of these genes remain to be characterized. By approach-
ing antibiotic resistance in nature not from an anthropocentric
viewpoint, but from bacterial evolution and ecological stand-
points will we be able to identify the origins and evolution of such
genes.
While soil may be a reservoir of antibiotic resistance genes,
but not all resistance mechanisms are necessarily a threat to the
continued use of antibiotics in all pathogens. Intrinsic resistance
is a characteristic of almost all isolates of the bacterial species
(Leclercq et al., 2011). Intrinsic resistance occurs when the antimi-
crobial activity of the drug is clinically insufficient or antimicrobial
resistance is innate, rendering it clinically ineffective (Leclercq
et al., 2011). The commonly believed theory of the role of the
soil resistome is that antibiotic production and resistance co-exist
in soil bacteria, as demonstrated by studies of antibiotic biosyn-
thetic pathways and genome analysis (Cases and de Lorenzo, 2005;
D’Costa et al., 2007). The theory is that without the resistance
gene the antibiotic producing bacteria would self-destruct, on
production of the antibiotic. However, Davies and Davies (2010)
pointed out that this theory remains to be proven. In order to
understand the importance of soil as a potential reservoir of antibi-
otic resistance mechanisms we need to investigate these theories.
The soil may be a reservoir of antibiotic resistance genes, but we
need to ask which resistance mechanisms are relevant to clinical
antibiotic use?
The human pathogen is not the ancestral home of antibi-
otic resistance as they have developed to infect humans, not to
live in soil with antibiotic producers. Therefore, if soil is the
natural reservoir of antibiotic resistance the most important resis-
tance mechanisms are those that can transfer from soil bacteria
to pathogenic bacteria. Thus, we need to study soil bacteria as
a reservoir of antibiotic resistance with relevance to the clinical
use of antibiotics. Another reason to study the soil resistome is to
understand the roles of antibiotics and resistance in nature: the
natural ecology and evolution of resistance. The idea is that by
learning more about how resistance has developed over time we
can understand antibiotic resistance evolution and spread within
patients and also help to predict the future evolution of resis-
tance to existing and novel antibiotics. Our use of antibiotics has
changed the course of antibiotic resistance ecology and evolu-
tion. The environment does not exist in a separate world to that
of humans. There is a constant flow to and from soil, especially
in urban and agricultural environments. Human activities such
as using antibiotics in the treatment of human and animal dis-
eases or in agriculture, but also pollution and climate change have
altered the soil environment. If the soil is a reservoir of antibi-
otic resistance mechanisms, we need to identify how our actions
and climatic change will also affect the soil resistome. The topic
of ecology and evolution of resistance in the environment will be
discussed in other papers within this special topic review and will
not be addressed in this review.
We frequently refer to bacteria as being resistant to antibiotics,
but rarely do we consider what that means. Even the most resis-
tant bacterium can be inhibited or killed by a sufficiently high
concentration of antibiotic; patients, however, would not be able
to tolerate the high concentration required in some cases (Hawkey,
1998). In order to study the antibiotic resistome, we need to know
what antibiotic and antibiotic resistance means in terms of soil
bacteria. Antibiotic action and resistance up until a few years ago
has been studied almost exclusively in terms of human or ani-
mal pathogens. We can separate the study of the soil antibiotic
resistome into two different contexts:
1. Clinical relevance: antibiotic resistance of relevance to
pathogens
2. Natural relevance: ecology and evolution of antibiotic resistance
These separations ensure that when we study antibiotic resis-
tance in clinical terms that we have a definition of antibiotics and
antibiotic resistance, as they are used in medicine. I will focus on
the clinical relevance for the remainder of this review. The term
antibiotic was described by Waksman (1973) as a description of
a use, a laboratory effect or an activity of a chemical compound.
Davies and Davies (2010) defined an antibiotic as any class of
organic molecule that inhibits or kills microbes by specific inter-
actions with bacterial targets, without any consideration of the
source of the particular compound or class. Antibiotic resistance
froma clinical viewpoint has been defined by the EuropeanAgency
for the evaluation of medicinal products, as microbiologically
resistant or clinically resistant2.
Microbiological resistance:
“Resistant microorganisms from a microbiological point of
view are those that possess any kind of resistance mechanism or
resistance gene.” This definition is quantified using MIC data and
breakpoints for the antibiotics.
Clinical resistance:
“The classification of a bacteria as susceptible or resistant
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Clinical resistance is a complex concept in which the type of
infecting bacterium, its location in the body, the distribution of the
antibiotic in the body and its concentration at the site of infection,
and the immune status of the patient all interact. The difficulty
ariseswhenwe try to apply these definitions to soil bacteria or non-
pathogenic bacteria, where no breakpoints exist. If we identify a
novel resistance mechanism in a soil bacteria, will this resistance
gene cause resistance in a human pathogen? The antibiotic resis-
tance definition of most relevance in both clinical and non-clinical
environments is that of the WHO:
Antimicrobial resistance is resistance of a microorganism to an
antimicrobial medicine to which it was previously sensitive.
In order to define antibiotic resistance in non-clinical environ-
ments we need to address the specific context and define what
is meant by sensitive. In terms of clinically relevant antibiotic
resistances, we can define resistance in all contexts as bacteria con-
taining a known resistance gene or those, which are no longer
inhibited at the site of infection. These bacteria would then be
considered resistant to the respective antibiotics. Defining an
antibiotic sensitive bacteria is a more complex task, especially with
respect to bacteria inhabiting different environments. A bacteria
defined as sensitive may be so in soil, but in the presence of clin-
ically relevant antibiotic concentrations, may be highly mutable
or have inducible resistance mechanisms. Thus, a sensitive bacte-
ria is one, which would not be readily selected in the presence of
higher concentrations of antibiotic than those concentrations in
the environment. If an environmental species in a particular place
increases its MIC to a certain antibiotic along a limited period
of time it can be considered that it has become “more” resistant
or less susceptible. However, defining resistance by the presence
of known resistance genes is limiting the search for resistance to
those already characterized. Thus, we propose that such resistance
genes be separated into pR-genes, potential resistance genes or
pre-resistance genes and aR-genes, genes known to produce an
antibiotic resistance phenotype in bacteria capable of survival and
integration into the human or animal microbiotia.
How do we decide which resistances are relevant? In clinical
practice we know that Pseudomonas aeruginosa is intrinsically
resistant to ampicillin due to chromosomally mediated AmpC,
efflux and impermeability. Therefore, clinical Pseudomonas aerug-
inosa are not tested for susceptibility to ampicillin as it is not
used to treat Pseudomonas aeruginosa infections. However, if soil
is described as a potential reservoir of resistance genes, which
can move from the chromosome to mobile elements and then
to pathogens we need to test all of the bacteria, not just the
pathogens or antibiotic producers. If we identify a penicillin resis-
tant Pedobacter species, does this mean that Pedobacter contains a
potential novel resistance gene or, like Pseudomonas aeruginosa it
is mediated by intrinsic resistance or that it is only or importance
if it can be expressed in pathogenic bacteria?
Novel resistance genes may be identified using functional
metagenomics; total soil DNA is extracted, digested, and ligated
into a vector. The vector is transferred into a bacterial host, e.g.,
Escherichia coli and the functional characteristics are measured
using clinical breakpoints (Handelsman, 2004). However, in hos-
pitals antibiotic resistance is generally tested using MIC or disk
diffusion assays. A definition of antibiotic resistance for antibiotic
susceptibility testing of bacteria in non-clinical environments is
required. The culture-based studies of antibiotic resistance in soil
bacteria to date have defined antibiotic resistance as growth at
20 mg/L (D’Costa et al., 2007; Bhullar et al., 2012). This arbitrary
definition is based on the use of 20 mg/L as the breakpoint concen-
tration in the initial soil resistome study of Streptomyces species
(D’Costa et al., 2007). This definition is used for all bacteria and
all classes of antibiotics.
The clinical breakpoint of an antibiotic is determined by com-
bining the relevant factors in setting breakpoints for antimicrobial
agents and consist of, as defined by the European Committee on
Antimicrobial Susceptibility Testing:
1. Available formulations
2. Standard and maximum dosing
3. Clinical indications and target organisms
4. MIC distributions for individual species
5. Pharmacokinetic (PK) data in humans
6. Pharmacodynamic (PD) data
7. Information from modeling processes
8. Clinical data relating outcome to MIC values
9. Information on resistance mechanisms, the clinical significance
of the resistance mechanisms, and the MICs for organisms
expressing the resistance mechanisms
However, where no PK/PD data for antibiotics with a particu-
lar species have been generated the breakpoints should be based
on epidemiological cut-off (ECOFF) values for the antibiotics3.
In the case of clinical infections these are limited to antibiotics
used to treat the infection. In a recent evaluation of Pasteurella
multocida by EUCAST the ECOFF values were determined using
approximately 250 isolates for the tests and were estimated by
visual inspection or statistically calculated (Turnidge et al., 2006).
Ideally greater than 250 isolates would be obtained from multi-
ple centers or countries in order to establish a worldwide ECOFF
values. Each country could then survey their own multi-center
sites in order to identify edaphic influences on the soil resistome.
Although the culturable bacteria represent less than 1% of the
total bacterial population, within this 1% remains a large number
of bacterial species, for which there are no antibiotic breakpoint
values. The possibility of culturingmanymore organisms than this
1% will be provided by the advances in “culturomics” and com-
bining metagenomics data with concurrent sequencing (Lagier
et al., 2012; VanInsberghe et al., 2013). In order to define a bac-
teria as resistant we need to test the MIC distribution within
the population and identify the breakpoint. Therefore, in terms
of defining antibiotic breakpoints for bacteria from non-clinical
environments the ECOFF would be the most appropriate. In order
to create breakpoints for these environmentswewould need to col-
lect and test at least 250 isolates fromdifferent locations, in order to
have a representative sample.With breakpointswe can set standard
guidelines for susceptibility testing of antibiotics in non-clinical
environments. Susceptibility testing is the gold standard of antibi-
otic resistance testing used throughout the world in hospitals.
It is a relatively cheap and easy technique with little need for
3http://www.eucast.org/
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sophisticated or expensive equipment. Therefore, using sus-
ceptibility testing would enable the comparison of non-clinical
data with clinical data. However, this is limited to culturable
bacteria.
Non-culture-based techniques are required to investigate the
entire bacterial community. The bacteria that can be grown in
the laboratory are only a small fraction of the total diversity that
exists in nature. Approximately only 1% of bacteria on Earth can
be readily cultivated in vitro (Staley and Konopka, 1985; Amann
et al., 2001). Therefore, non-culture-based tools such as PCR and
metagenomics are required to capture the non-culturable section
of the non-clinical antibiotic resistome. However, one disadvan-
tage of these tools are that they are limited to screening for known
resistance genes and mechanisms and identification of only the
resistance gene rather than being able to investigate the process
involved in resistance, as with culturable bacteria. PCR and quan-
titative PCR have been frequently used to determine the presence
of resistance genes in nature and the effects of agriculture on the
emergence and spread of resistance. The most frequently used
methods to determine the presence of antibiotic resistance in the
environment have been PCR detection, microarray detection or
real-time PCR detection of known resistance genes (Chen et al.,
2007; Koike et al., 2007; Peak et al., 2007; Walsh and Rogers,
2008; Borjesson et al., 2009; Walsh et al., 2010). These techniques
are limited to detecting genes, which are known and have been
sequenced. More recently functional metagenomics have iden-
tified novel resistance genes and antibiotic biosynthesis genes
present in environmental bacteria (Donato et al., 2010; Torres-
Cortés et al., 2011). The direct applications of sequencing have to
date been mostly focused on the elucidation of species variations
within the environment (Kohler et al., 2005; Janssen, 2006; Lauber
et al., 2009; Shange et al., 2012).
The application of functional metagenomics on soil DNA
have identified novel resistance genes and antibiotic biosyn-
thesis genes present in environmental bacteria (Donato et al.,
2010; Torres-Cortés et al., 2011). Functional metagenomics is the
genomic study, without culturing, of a population of microor-
ganisms (Handelsman, 2004). This approach has been applied to
the study of the antibiotic resistome present in environmental
samples (Riesenfeld et al., 2004; Donato et al., 2010; Torres-
Cortés et al., 2011). The advantages of metagenomics are that
the bacterial community can be analyzed for antibiotic resistance
genes without the need to culture these organisms and can be
used to detect as yet unknown antibiotic resistance genes. The
gene’s function is expressed as the antibiotic resistance pheno-
type in the host bacteria. However, the disadvantage lies with
the fact that the host bacteria is frequently Escherichia coli, which
may not be capable of expressing all of the resistance genes,
e.g., strA.
Antibiotic resistance genes and plasmids have been identified
in pristine and agricultural ecosystems using PCR, functional
metagenomics and pyrosequencing tools (Pruden et al., 2006;
Allen et al., 2009; Heuer and Smalla, 2012). Both novel resistance
genes and bifunctional genes were identified in soil from apple
orchards (Donato et al., 2010). The revolution in high-throughput
sequencing has brought unique opportunities and challenges to
the field of environmental microbiology. Since its introduction
in 2005, the number of metagenomic libraries in the database
has increased year by year and following the quantum leaps of
next generation sequencing techniques (Schmieder and Edwards,
2012). Dependent on the sequencing platform, up to 500 Gb
of sequencing data can be generated per single run (Shokralla
et al., 2012).
The complete characterization of the soil antibiotic resistome
requires both culture and non-culture-based approaches. Using
defined guidelines and definitions the scientific community can
standardize the methodologies required. This has proved very
effective in the surveillance of antibiotic resistance, emerging
trends, and novel resistance mechanisms in clinical bacteria. The
advantage of identifying the bacteria associated with the resis-
tance mechanism, if it is a novel mechanism, is that the entire
genetic cascade or pathway leading to resistance can be studied in
depth. However, culture-based techniques alone will only describe
a small fraction of the bacteria present in non-clinical environ-
ments. A combination of culture-based and non-culture-based
standardized techniques will provide a wealth of information on
the composition of the non-clinical antibiotic resistome. The
WHO definition of resistance is the most fitting to non-clinical
environmental studies. The ideal investigation of non-clinical
environments for antibiotic resistance of clinical relevance would
be using standardized guidelines and breakpoints as outlined in
this review.
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